Summary
In recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunotherapy to the combination of targeted agents (BTK inhibitors, BCL2 inhibitors, anti-CD20 antibody), which should be administered in a time-limited manner when possible. This was also recognized in the Onkopedia Guidelines, which were recently updated [1]. At the last American Society of Hematology (ASH) meeting in San Diego (CA, USA), this trend was reflected in almost all presentations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wendtner CM, Al-Sawaf O, Binder M, Dreger P, Eichhorst B, Gregor M, et al. Onkopedia Guidelines für CLL. 2023.
Hillmen P, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt, et al. Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR study. ASH 2023. p. Abstract 631.
Eichhorst B, Niemann C, Kater A, Fürstenau M, Von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739–54.
Fürstenau M, Ritgen M, Robrecht S, Von Tresckow J, Zhang C, Schilhabel A, et al. First-line venetoclax combinations in fit patients with CLL: 4‑year follow-up and NGS-based MRD analysis from the phase 3 GAIA/CLL13 trial. ASH 2023. p. Abstract 635.
Moreno C, Munir T, Owen C, Follows G, Hernandez Rivas JA, Benjamini O, et al. First-line fixed-duration Ibrutinib plus Venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the glow study. Abstract 634. ASH 2023.
Sharman J, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, et al. Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in treatment-naive chronic lymphocytic leukemia: 6‑year follow-up of elevate-TN. ASH 2023. p. Abstract 636.
Tam C, Anderson MA, Lasica M, Verner E, Opat S, Ma S, et al. Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study. ASH 2023, Abstract 327
Brown J, Eichhorst B, Lamanna N, O´Brien S, Tam C, Qiu L, et al. Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus Ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic Lymphoma (R/R CLL/SLL). ASH 2023. p. Abstract 202.
Woyach J, Brown J, Ghia P, Roeker L, Patel K, Eyre T, et al. Pirtobrutinib in post-cBTKi CLL/SLL: ~30 months follow-up and subgroup analysis with/without prior BCL2i from the phase 1/2 BRUIN study. ASH 2023. p. Abstract 325.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, et al. Tislelizumab plus zanubrutinib in patients with richter transformation: primary endpoint analysis of the prospective, multi-center, phase-II RT1 trial of the German CLL study group. ASH 2023. p. Abstract 204.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
T. Nösslinger declares potential conflicts of interest: Abbvie, Astra Zeneca, Beigene, Janssen, Lilly, Roche.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nösslinger, T. American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia. memo (2024). https://doi.org/10.1007/s12254-024-00971-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12254-024-00971-z